Knight Therapeutics (OTCMKTS:KHTRF – Get Rating) had its price objective cut by Knight Equity from C$8.00 to C$7.00 in a research note published on Friday, The Fly reports. Separately, Stifel Nicolaus cut Knight Therapeutics from a buy rating to a hold rating and lowered their price objective for the company from C$7.00 to C$5.30 in […]